These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
707 related articles for article (PubMed ID: 36305410)
1. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers]. Liu J; Xu K; Ma L; Wang Y Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410 [TBL] [Abstract][Full Text] [Related]
2. Prediction and analysis of hub genes between glioblastoma and low-grade glioma using bioinformatics analysis. Xu B Medicine (Baltimore); 2021 Jan; 100(3):e23513. PubMed ID: 33545929 [TBL] [Abstract][Full Text] [Related]
3. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry. Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924 [TBL] [Abstract][Full Text] [Related]
4. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma. Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951 [TBL] [Abstract][Full Text] [Related]
5. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data. Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666 [TBL] [Abstract][Full Text] [Related]
6. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy. Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X Front Immunol; 2022; 13():899710. PubMed ID: 35677036 [TBL] [Abstract][Full Text] [Related]
7. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas. Tian QS; Zhang Q; Huang W Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806 [TBL] [Abstract][Full Text] [Related]
8. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma. Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB Front Immunol; 2020; 11():606164. PubMed ID: 33408717 [TBL] [Abstract][Full Text] [Related]
9. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma. Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355 [TBL] [Abstract][Full Text] [Related]
10. Identification of potential biomarkers related to glioma survival by gene expression profile analysis. Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197 [TBL] [Abstract][Full Text] [Related]
11. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy. Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K Front Immunol; 2023; 14():1166377. PubMed ID: 37063864 [TBL] [Abstract][Full Text] [Related]
12. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis. Qi C; Lei L; Hu J; Wang G; Liu J; Ou S J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801 [TBL] [Abstract][Full Text] [Related]
13. Integrated Gene Expression and Methylation Analyses Identify DLL3 as a Biomarker for Prognosis of Malignant Glioma. Maimaiti A; Wang X; Hao Y; Jiang L; Shi X; Pei Y; Feng Z; Kasimu M J Mol Neurosci; 2021 Aug; 71(8):1622-1635. PubMed ID: 33713320 [TBL] [Abstract][Full Text] [Related]
14. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma. Hao YP; Wang WY; Qiao Q; Li G Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884 [TBL] [Abstract][Full Text] [Related]
15. Identification of Hub Gene GRIN1 Correlated with Histological Grade and Prognosis of Glioma by Weighted Gene Coexpression Network Analysis. Yang A; Wang X; Hu Y; Shang C; Hong Y Biomed Res Int; 2021; 2021():4542995. PubMed ID: 34840971 [TBL] [Abstract][Full Text] [Related]
16. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas. Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L Front Immunol; 2020; 11():603341. PubMed ID: 33363544 [TBL] [Abstract][Full Text] [Related]
17. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas. Zhao WJ; Ou GY; Lin WW Front Immunol; 2021; 12():682415. PubMed ID: 34054873 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower-grade gliomas. Ji Q; Huang K; Jiang Y; Lei K; Tu Z; Luo H; Zhu X Cancer Med; 2022 May; 11(9):2020-2035. PubMed ID: 35142109 [TBL] [Abstract][Full Text] [Related]
19. Identification of genes related to low-grade glioma progression and prognosis based on integrated transcriptome analysis. Jiang Y; He J; Guo Y; Tao H; Pu F; Li Y J Cell Biochem; 2020 Jun; 121(5-6):3099-3111. PubMed ID: 31886582 [TBL] [Abstract][Full Text] [Related]
20. Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas. Ye L; Tong S; Wang Y; Wang Y; Ma W J Cancer Res Clin Oncol; 2023 Sep; 149(12):9857-9876. PubMed ID: 37248320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]